AR058110A1 - Derivados de piperidina - Google Patents

Derivados de piperidina

Info

Publication number
AR058110A1
AR058110A1 ARP060105599A ARP060105599A AR058110A1 AR 058110 A1 AR058110 A1 AR 058110A1 AR P060105599 A ARP060105599 A AR P060105599A AR P060105599 A ARP060105599 A AR P060105599A AR 058110 A1 AR058110 A1 AR 058110A1
Authority
AR
Argentina
Prior art keywords
membered heteroaryl
phenyl
group
alkyl
formula
Prior art date
Application number
ARP060105599A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR058110A1 publication Critical patent/AR058110A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Composiciones farmacéuticas; procedimientos, para tratar estados patologicos, enfermedades y trastornos como fibromialgia, ansiedad, depresion, esquizofrenia, déficit de atencion. Reivindicacion 1: Un compuesto de formula (1) o una de sus sales farmacéuticamente aceptables, en la que las posiciones del grupo piperidinilo de formula (1) están marcadas como 1, 2, 3, 4, 5 o 6; 10 es como se muestra en formula (2), un tienopiridinilo, un heteroarilo de 5 miembros o un heteroarilo de 6 miembros; R1, R2, R3, R4 y R5 se seleccionan independientemente del grupo consistente en H, -O-cicloalquilo C5-7, cicloalquilo C5-7, -O-heterocicloalquilo C5-7, -heterocicloalquilo C5-7, -O-fenilo, fenilo, alquileno C1-4-NR16R18, alquilo C1-4, alcoxi C1-4, halo, -C(O)NR12R14, -SO2-CH3, -SO2-CH2CH3, y CN; pudiendo estar dichos tienopiridinilo, heteroarilo de 5 miembros o heteroarilo de 6 miembros opcionalmente sustituidos con 1 a 3 sustituyentes seleccionados independientemente del grupo consistente en H, -O-cicloalquilo C5-7, cicloalquilo C5-7, -O-heterocicloalquilo C5-7, -heterocicloalquilo C5-7, -O-fenilo, -O-(CH2)n-fenilo, -(CH2)n-fenilo, fenilo, -O-(heteroarilo de 5- o 6-miembros), -O-(CH2)n-(heteroarilo de 5- o 6-miembros), - (CH2)n-(heteroarilo de 5- o 6-miembros), alquileno C1-4-NR16R18, alquilo C1-4, alcoxi C1-4, halo, -C(O)NR12R14, -SO2-CH3, -SO2-CH2CH3, y CN; n es 1,2 o 3; R12 y R14 se seleccionan independientemente del grupo consistente en H y alquilo C1-4; R16 y R18 se seleccionan independientemente del grupo consistente en H y alquilo C1-4, y R6 es H o 1 a 3 sustituyentes seleccionados independientemente del grupo consistente en alquilo C1-4, alcoxi C1-4 y halo; con la condicion de que cuando R10 es como en formula (2), y R1, R2, R4 y R5 son H, entonces R3 no es alcoxi C1-4; y cuando R10 es como en formula (2), entonces uno de R1, R2, R3, R4, R5 y R6 no es H.
ARP060105599A 2005-12-20 2006-12-18 Derivados de piperidina AR058110A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75184505P 2005-12-20 2005-12-20

Publications (1)

Publication Number Publication Date
AR058110A1 true AR058110A1 (es) 2008-01-23

Family

ID=38015373

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105599A AR058110A1 (es) 2005-12-20 2006-12-18 Derivados de piperidina

Country Status (12)

Country Link
US (1) US20070142389A1 (es)
EP (1) EP1966137A2 (es)
JP (1) JP2009520018A (es)
AR (1) AR058110A1 (es)
CA (1) CA2634172A1 (es)
DO (1) DOP2006000287A (es)
GT (1) GT200600516A (es)
NL (2) NL2000376C2 (es)
PE (1) PE20071005A1 (es)
TW (1) TW200732304A (es)
UY (1) UY30029A1 (es)
WO (1) WO2007072150A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059393A1 (en) * 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Serotonin receptor modulators
WO2010059390A1 (en) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Modulators of serotonin receptor
RU2503662C2 (ru) 2008-11-14 2014-01-10 Тереванс, Инк. Кристаллическая форма 4-[2-(2-фторфеноксиметил)фенил]пиперидинового соединения
US8778949B2 (en) * 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
CN104039777B (zh) * 2012-01-31 2016-03-02 卫材R&D管理有限公司 帕罗西汀衍生物
CN114773318A (zh) * 2015-09-02 2022-07-22 特维娜有限公司 含有六元氮杂杂环的δ阿片受体调节化合物、其使用和制备方法
AU2018221148B2 (en) 2017-02-17 2022-05-05 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
BR112019016775A2 (pt) 2017-02-17 2020-03-31 Trevena, Inc. Compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 7 membros, métodos de uso e produção dos mesmos
CN111533682B (zh) * 2020-05-29 2022-03-01 清华大学 帕罗西汀及其类似物的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
IE45511B1 (en) * 1976-09-01 1982-09-08 Ciba Geigy Ag New derivatives of perhydro-aza-heterocycles and processesfor the production thereof
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
DK231088D0 (da) * 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
US5227379A (en) * 1986-11-03 1993-07-13 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5017585A (en) * 1986-11-03 1991-05-21 Novo Nordisk A/S Method of treating calcium overload
IL98757A (en) * 1990-07-18 1997-01-10 Novo Nordisk As Piperidine derivatives their preparation and pharmaceutical compositions containing them
US5808139A (en) * 1992-04-21 1998-09-15 Ligand Pharmaceuticals Incorporated Non-steroid progesterone receptor agonist and antagonist and compounds and methods
US5914328A (en) * 1992-10-09 1999-06-22 Abbott Laboratories Heterocyclic ether compounds useful in controlling neurotransmitter release
NZ315677A (en) * 1995-09-07 2000-02-28 F 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
US20020151712A1 (en) * 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
WO2001032178A1 (en) * 1999-10-29 2001-05-10 Novo Nordisk A/S Use of 3,4-substituted piperidines
US20040087795A1 (en) * 2000-07-17 2004-05-06 Borrett Gary Thomas Novel processes for the preparation of 4-phenylpiperidine derivatives
EP1417174A2 (en) * 2001-08-08 2004-05-12 Neurosearch A/S Substituted amine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Also Published As

Publication number Publication date
NL2000376A1 (nl) 2007-06-21
UY30029A1 (es) 2007-07-31
CA2634172A1 (en) 2007-06-28
NL2000937A1 (nl) 2008-01-11
NL2000937C2 (nl) 2008-07-22
PE20071005A1 (es) 2007-10-24
JP2009520018A (ja) 2009-05-21
DOP2006000287A (es) 2007-11-30
GT200600516A (es) 2007-08-21
WO2007072150A2 (en) 2007-06-28
EP1966137A2 (en) 2008-09-10
TW200732304A (en) 2007-09-01
NL2000376C2 (nl) 2007-10-24
WO2007072150A3 (en) 2008-05-29
US20070142389A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
AR058110A1 (es) Derivados de piperidina
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
MEP22008A (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
PE20091005A1 (es) N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas
AR070992A1 (es) Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1
AR043700A1 (es) Derivados de 3-substituida-4-pirimidona
NI200800036A (es) Inhibidores macrociclicos del virus de la hepatitis c
PE20080318A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
AR060604A1 (es) Nuevos arilamino n- heteroarilos como inhibidores de mek
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CO5611126A2 (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa
HRP20090101T3 (en) N-(1h-indolyl)-h-indole-2-carboxamide derivatives, their preparation and their therapeutic use
AR077440A1 (es) Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas
HN2005000370A (es) Derivados de pirido-pirimidina, su preparacion y su aplicacion en terapeutica
AR041298A1 (es) Derivados de pirrolidona como inhibidores de maob
RS51358B (en) N- (HETEROARYL) -1H-INDOL-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS A VANYLOID TRPV1 RECEPTOR LIGAND
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
CO5650235A2 (es) Derivados de imidazol
AR064424A1 (es) Derivados sustituidos de 1-oxo-ftalazinas y 1-oxo-pirido-piridazinas,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar enfermedades inflamatorias y alergicas del tracto respiratorio.

Legal Events

Date Code Title Description
FB Suspension of granting procedure